Evidence map›Paper›PMID 33359448›Full record

ArticleCancer letters2021

The anti-tumour activity of DNA methylation inhibitor 5-aza-2'-deoxycytidine is enhanced by the common analgesic paracetamol through induction of oxidative stress.

Hannah J Gleneadie, Amy H Baker, Nikolaos Batis, Jennifer Bryant, Yao Jiang, Samuel J H Clokie, Hisham Mehanna, Paloma Garcia, Deena M A Gendoo, Sally Roberts and 8 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Antiphotoaging and Skin-Protective Activities ofPlants (Basel, Switzerland) · 2023
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 3 countries.

Hannah J GleneadieSchool of Dentistry, Institute of Clinical Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B5 7EG, UK; Present Address: MRC London Institute of Medical Sciences, Imperial College London, London, W12 0NN, UK.
Amy H BakerSchool of Dentistry, Institute of Clinical Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B5 7EG, UK.
Nikolaos BatisInstitute of Head and Neck Studies and Education (InHANSE), The University of Birmingham, Birmingham, B15 2TT, UK.
Jennifer BryantInstitute of Head and Neck Studies and Education (InHANSE), The University of Birmingham, Birmingham, B15 2TT, UK.
Yao JiangInstitute of Clinical Sciences, The University of Birmingham, Birmingham, B15 2TT, UK.
Samuel J H ClokieWest Midlands Regional Genetics Laboratory, Birmingham Women's and Children's Hospital, Birmingham, B15 2TG, UK.
Hisham MehannaInstitute of Head and Neck Studies and Education (InHANSE), The University of Birmingham, Birmingham, B15 2TT, UK.
Paloma GarciaInstitute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B15 2TT, UK.
Deena M A GendooCentre for Computational Biology, Institute of Cancer and Genomic Sciences, The University of Birmingham, Birmingham, B15 2TT, UK.
Sally RobertsInstitute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B15 2TT, UK.
Megan BurleyInstitute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B15 2TT, UK.
Alfredo A MolinoloMoores Cancer Center and Department of Pathology, University of California San Diego, La Jolla, CA, 92093, USA.
J Silvio GutkindDepartment of Pharmacology and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Ben A SchevenSchool of Dentistry, Institute of Clinical Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B5 7EG, UK.
Paul R CooperSchool of Dentistry, Institute of Clinical Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B5 7EG, UK; Present Address: Sir John Walsh Research Institute, University of Otago, Dunedin, New Zealand.
Joanna L ParishInstitute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B15 2TT, UK.
Farhat L KhanimInstitute of Clinical Sciences, The University of Birmingham, Birmingham, B15 2TT, UK.
Malgorzata WienchSchool of Dentistry, Institute of Clinical Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B5 7EG, UK; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, The University of Birmingham, Birmingham, B15 2TT, UK. Electronic address: m.d.wiench@bham.ac.uk.
University of Birmingham · GBUniversity of California San Diego · USBirmingham Women's Hospital · GBMRC London Institute of Medical Sciences · GB

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
Targeting Signaling Vulnerabilities for Oral Cancer PreventionR01DE026644 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jorge Silvio Gutkind, SCOTT M LIPPMAN · 2017 to 2026
$4.7M
Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision TherapyR01DE026870 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUTKIND, JORGE SILVIO · 2018 to 2022
$2.3M
Cancer Research UKDepartment of Health 06/302/129Medical Research Council MR/N023498/1Medical Research Council MR/R022011/1Medical Research Council MR/S005498/1Medical Research Council MR/T015985/1NCI NIH HHS P30 CA023100NIDCR NIH HHS R01 DE026870
6 · The paper itself

Abstract

The DNA demethylating agent 5-aza-2'-deoxycytidine (DAC, decitabine) has anti-cancer therapeutic potential, but its clinical efficacy is hindered by DNA damage-related side effects and its use in solid tumours is debated. Here we describe how paracetamol augments the effects of DAC on cancer cell proliferation and differentiation, without enhancing DNA damage. Firstly, DAC specifically upregulates cyclooxygenase-2-prostaglandin E

Indexed as

AcetaminophenAnimalsAntimetabolites, AntineoplasticCell DifferentiationCell Line, TumorCell ProliferationDecitabineDrug SynergismHead and Neck NeoplasmsHL-60 CellsHumansLeukemia, MyeloidMaleMiceOxidative StressReactive Oxygen SpeciesAcetaminophenAntimetabolites, AntineoplasticDecitabineReactive Oxygen SpeciesSuperoxidesAcetaminophenAcute myeloid leukaemiaDecitabineEpigenetic therapiesHead and neck squamous cell carcinoma

Identifiers

PMID33359448
PMCPMC7845757
OpenAlexW3114278012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.